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Macrophage migration inhibitory factor (MIF) is a pleiotropic, constitutively expressed, 
pro-inflammatory cytokine and an important regulator of immune responses. 
 d- dopachrome tautomerase (DDT), a newly described member of the MIF protein 
superfamily, shares sequence homology and biological activities with MIF. We recently 
reported that high expression levels of MIF sustain innate immune responses in new-
borns. Here, we elected to further characterize age-dependent MIF expression and to 
define whether DDT shares a similar expression profile with MIF. Therefore, we delineated 
the circulating concentrations of MIF and DDT throughout life using a large cohort of 
307 subjects including fetuses, newborns, infants, children, and adults. Compared to 
levels measured in healthy adults (median: 5.7 ng/ml for MIF and 16.8 ng/ml for DDT), 
MIF and DDT plasma concentrations were higher in fetuses (median: 48.9 and 29.6 ng/
ml), increased further at birth (median: 82.6 and 52.0 ng/ml), reached strikingly elevated 
levels on postnatal day 4 (median: 109.5 and 121.6  ng/ml), and decreased to adult 
levels during the first months of life. A strong correlation was observed between MIF and 
DDT concentrations in all age groups (R = 0.91, P < 0.0001). MIF and DDT levels cor-
related with concentrations of vascular endothelial growth factor, a protein upregulated 
under low oxygen tension and implicated in vascular and lung development (R = 0.70, 
P < 0.0001 for MIF and R = 0.65, P < 0.0001 for DDT). In very preterm infants, lower 
levels of MIF and DDT on postnatal day 6 were associated with an increased risk of 
developing bronchopulmonary dysplasia and late-onset neonatal sepsis. Thus, MIF and 
DDT plasma levels show a highly specific developmental profile in early life, supporting 
an important role for these cytokines during the neonatal period.
Keywords: macrophage migration inhibitory factor, d-dopachrome tautomerase, innate immunity, fetus, neonate, 
healthy adult, bronchopulmonary dysplasia, sepsis
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inTrODUcTiOn
Macrophage migration inhibitory factor (MIF) is a pleiotropic 
cytokine that is constitutively expressed by virtually all cell 
types and tissues and circulates in the bloodstream of healthy 
adults at around 2–10 ng/ml (1). MIF promotes inflammatory, 
proliferative, and angiogenic biological activities and is involved 
in the pathogenesis of infectious, inflammatory, autoimmune, 
and neoplastic diseases (1, 2). Accordingly, MIF blood levels are 
increased in patients with arthritis (3), systemic lupus erythe-
matosus (4), psoriasis (5), atopic dermatitis (6), ulcerative colitis 
(7), asthma (8), and cancer (9). MIF levels are also increased in 
the circulation of septic patients and correlate with dysregulated 
pituitary and adrenal function, inflammatory response, severity 
scores, and disease outcome (10–13). Functional polymor-
phisms of the MIF gene affecting MIF expression levels have 
been associated with susceptibility to or severity of autoimmune, 
infectious, and oncologic diseases (14–17). Altogether, MIF 
is considered as a potential biomarker/genetic marker and an 
attractive target for immunomodulating therapies for a number 
of diseases (14, 15, 18–24).
Macrophage migration inhibitory factor is produced by many 
organs and tissues during embryonic and fetal development and 
promotes lung development in mice (25–27). In humans, MIF is 
present in the amniotic fluid and is expressed in the fetal mem-
branes of the placenta and in the fetal and neonatal lungs (28–31). 
Interestingly, circulating levels of MIF are at least 10-fold higher 
in healthy term newborns than in adults (30, 32, 33). We recently 
reported that high expression levels of MIF sustain innate immune 
responses of newborn monocytes and counter-regulate the activ-
ity of adenosine and prostaglandin E2, two immunosuppressive 
mediators produced at high levels by the placenta (33). Thus, MIF 
may play an important role in the developmental regulation of 
immune responses (33).
d-dopachrome tautomerase (DDT, also known as MIF-2) is 
the second member of the MIF protein superfamily (34). DDT 
and MIF are encoded by adjacent genes and share 34% amino 
acid identity in humans. DDT is constitutively expressed in the 
lungs, kidney, liver, spleen, heart, intestine, brain, and immune 
cells and circulates in the low nanograms per milliliter range in 
healthy individuals (35). Like MIF, DDT forms homotrimers and 
binds to the MIF receptor CD74. MIF and DDT induce similar 
signaling mechanisms and have overlapping biological activities, 
although much less is known about DDT than MIF. Blood levels of 
DDT are elevated in burn, septic, and cancer patients, and during 
cardiac surgery, and correlate with disease severity and clinical 
outcome (35–37). DDT, but not MIF, is a valuable biomarker to 
predict clinical outcome and sepsis occurrence after burn injury 
(36). So far, circulating levels of DDT in newborns and children 
have not been reported.
We hypothesized that levels of both MIF and DDT would be 
elevated in early life, at a period critical for the development of the 
lungs and the immune system, and that MIF and DDT could be 
attractive biomarker candidates in newborns. Concentrations of 
MIF and DDT were determined in a large cohort of different age 
groups including fetuses, preterm and term newborns, infants, 
children, and adults to get more insights into the developmental 
profile of MIF and DDT and establish reference intervals. 
Moreover, we correlated MIF and DDT levels with inflammatory 
and clinical parameters and outcome in very preterm infants 
who are at risk of developing severe complications including 
bronchopulmonary dysplasia (BPD) and late-onset neonatal 
sepsis (LOS).
sUbjecTs anD MeThODs
subjects and source of Plasma samples
Plasma samples were obtained from 307 subjects from 5 groups. 
The first group comprised 15 fetuses in which blood samples 
were collected by cordocentesis prior to therapeutic abor-
tions performed in the context of congenital malformations 
or chromosomal abnormalities (38). This study was approved 
by the Ethics Committee of the Erasme Hospital (Brussels, 
Belgium). The second group comprised 60 healthy term and 34 
preterm neonates born at the University Hospital of Lausanne, 
Switzerland. Infants with congenital malformations, chromo-
somal abnormalities, perinatal asphyxia, and maternal, fetal, 
or neonatal infection were excluded. Cord blood was collected 
from the umbilical artery (UA) and the umbilical vein (UV) 
after delivery of the placenta. Peripheral blood was collected on 
postnatal day 4 in 12 healthy term newborns. The third group 
comprised 17 infants (aged between 1 and 12  months) and 73 
children (aged between 1 and 16  years) admitted for elective 
surgery at the Department of Pediatrics, University Hospital of 
Lausanne, Switzerland (33, 39). Infants and children with acute 
or chronic infection, severe underlying disease, or chromosomal 
abnormality were excluded from the study. Peripheral blood 
was collected by venous puncture prior to surgery. The surgical 
procedures are listed in Table S1 in Supplementary Material. The 
fourth group included 58 healthy adult volunteers (>16  years 
old). In groups 1–4, heparinized blood samples were collected, 
and plasma was stored at −80°C until analysis. A complete blood 
count was performed in UV blood from 25 patients from group 
2, using a Beckman Coulter ACT diff analyzer. The study with 
second, third, and fourth groups was approved by the Cantonal 
Ethics Committee of Vaud (Lausanne, Switzerland). The fifth 
group comprised 50 premature infants born before 32 weeks of 
gestation at the University Hospital of Zurich, Switzerland (40). 
Infants with complex congenital malformations, chromosomal 
abnormalities, and those who died within the first week after 
admission were excluded from the study. BPD was defined as 
requirement for supplemental oxygen for the first 28 days of life. 
LOS was defined as signs or symptoms of infection occurring at 
a postnatal age over 72 h in an infant with positive blood cultures 
and treated for at least 5  days with antibiotics. Blood samples 
were collected in EDTA tubes on postnatal day 6, and plasma 
was stored at −20°C until analysis. The study was approved by the 
Cantonal Ethics Committee of Zurich. All subjects from the five 
groups or their legal guardians gave written informed consent in 
accordance with the Declaration of Helsinki.
Measurement of MiF levels in Plasma
Macrophage migration inhibitory factor levels were measured 
by enzyme-linked immunosorbent assay (ELISA), using the 
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four-span approach, as previously described (41). Briefly, 96-well 
microtiter plates were coated with a duck anti-chicken antibody. 
Anti-human MIF polyclonal antibodies raised in chicken and 
rabbit were used as capture and trapping antibodies. A horse-
radish peroxidase-labeled goat anti-rabbit antibody was used 
for detection. Recombinant human MIF was used as a standard. 
The analytic sensitivity of the human MIF ELISA was 39 pg/ml. 
Intrarun and interrun coefficients of variation were 6 and 12%, 
respectively.
Measurement of MiF secretion by 
leukocyte subsets
Umbilical cord blood mononuclear cells from healthy term 
newborns and peripheral blood mononuclear cells from adult 
volunteers were obtained as previously described (33, 42). 
Neutrophils, monocytes, B cells, and T cells were isolated from 
mononuclear cells using magnetic microbeads (Miltenyi Biotec) 
coupled to antibodies directed against CD15, CD14, CD19, and 
CD3, respectively. Cells (105/well in 96-well plates) were cultured 
in RPMI medium 1640 supplemented with 10% fetal calf serum. 
MIF levels were measured by ELISA (R&D Systems) in cell cul-
ture supernatant collected at 24 and 48 h.
Measurement of DDT levels in Plasma
d-dopachrome tautomerase levels were measured by ELISA as 
previously described (35). Briefly, 96-well microtiter plates were 
coated with rabbit polyclonal antibodies raised against recombi-
nant human DDT. Wells were washed and blocked in 1% BSA and 
1% sucrose. Samples were added and incubated for 2 h, followed 
by biotinylated anti-DDT antibody and a streptavidin–HRP 
conjugate. DDT concentrations were calculated by extrapolation 
from a sigmoidal quadratic standard curve obtained using recom-
binant human DDT used as a standard. The analytic sensitivity of 
the DDT ELISA was 15 pg/ml. Intrarun and interrun coefficients 
of variation were 8 and 10%, respectively.
Measurement of TnF, il-1β, il-6, il-8, and 
Vascular endothelial growth Factor (VegF) 
levels in Plasma
Levels of TNF, IL-1β, IL-6, IL-8, and VEGF were measured using 
a ProcartaPlex panel (Affimetrix eBioscience) and a Luminex 200 
System analyzer (Luminex Corporation). Concentrations were 
calculated by extrapolation from a sigmoidal quadratic standard 
curve obtained using recombinant human standards. The limits 
of quantification of TNF, IL-1β, IL-6, IL-8, and VEGF were 6.52, 
2.05, 8.15, 2.17, and 5.74 pg/ml, respectively.
statistical analyses
Data are presented as median and interquartile range (IQR) and 
as mean and SD. Comparisons between groups were performed 
by Kruskal–Wallis and Mann–Whitney tests. Correlations 
between MIF and DDT levels and clinical variables were assessed 
by the non-parametric Spearman test. Exploratory multivariate 
analyses were performed on the composite outcome of BPD 
and/or LOS using logistic regression. Covariates associated with 
the outcome at a P value level of <0.1 were considered. Final 
models were adjusted for birthweight, given the strong influence 
of birthweight on outcomes in premature infants (43). Findings 
were considered statistically significant when P < 0.05. Statistical 
analyses were performed using Prism 7 (GraphPad Software, La 
Jolla, CA, USA) and IBM SPSS Statistics 22.
resUlTs
MiF and DDT Plasma levels in Different 
age groups
Plasma concentrations of MIF and DDT were measured in 15 
fetuses (at 20–36 weeks gestation), 60 term newborns (at birth), 
12 term newborns (on postnatal day 4), 17 infants (1–12 months 
old), 73 children (1–16  years old), and 58 adults (>16  years 
old). Strikingly, MIF concentrations were 5- to 20-fold higher in 
fetuses (median 48.9 ng/ml, IQR 33.2–65.0) and in healthy term 
newborns at birth (82.6 ng/ml, 66.1–115.4) and on postnatal day 
4 (109.5 ng/ml, 76.5–159.5) than in infants (7.4 ng/ml, 6.6–10.8), 
children (5.2  ng/ml, 3.4–7.7), and adults (5.7  ng/ml, 4.0–8.3) 
(P < 0.05; Table 1; Figure 1A). Similarly, DDT concentrations 
were 3- to 10-fold higher in healthy term newborns at birth 
(52.0  ng/ml, 43.9–72.4) and on postnatal day 4 (121.6  ng/ml, 
74.1–137.3) than in infants (14.6  ng/ml, 11.2–19.6), children 
(12.5  ng/ml, 9.1–16.3), and adults (16.8  ng/ml, 14.1–25.4) 
(P  <  0.05; Figure  1B). DDT concentrations in healthy term 
newborns on postnatal day 4 were also significantly higher than 
in fetuses (29.6 ng/ml, 18.9–45.6) (P < 0.05; Table 1). Overall, 
MIF and DDT concentrations were high in fetuses, even higher 
in term newborns at birth and on postnatal day 4, and decreased 
to the adult levels during the first months of life. A regression 
analysis of paired measurements revealed a strong correlation 
between MIF and DDT concentrations (R =  0.91, P <  0.0001; 
Figure 1C).
MiF and DDT levels in Umbilical  
cord blood at birth
To determine whether high concentrations of MIF and DDT in 
newborns are of fetal or placental origin, we compared MIF and 
DDT concentrations in the UA that drives blood flowing from the 
fetus to the placenta with that in the UV that drives blood flowing 
from the placenta to the fetus (44). The clinical characteristics of 
the 34 preterm and 60 term newborns selected for these measures 
are presented in Table 2. Median (IQR) gestational age was 34 
(32–36) and 39 (39–40) weeks for preterm and term newborns, 
respectively. MIF and DDT concentrations in the UA correlated 
with the concentrations measured in the UV (R = 0.43, P < 0.0001 
for both MIF and DDT; Figure 2) and were not different from 
each other (P = 0.33 for MIF and P = 0.71 for DDT). Thus, high 
levels of MIF and DDT in the circulation of newborns can be of 
fetal or placental origin.
In preterm newborns, median UV MIF and DDT concen-
trations were 58.3 and 58.7  ng/ml, respectively (Table  3). MIF 
concentrations in UV correlated with gestational age (R = 0.30, 
P = 0.004) and birthweight (R = 0.22, P = 0.04), while no such 
correlation was found for DDT (Figure  3). MIF and DDT 
FigUre 1 | Plasma concentrations of macrophage migration inhibitory factor (MiF) and d-dopachrome tautomerase (DDT) in healthy subjects from 
birth to adulthood. MIF (a) and DDT (b) plasma concentrations in the umbilical vein of 60 healthy term newborns and in the peripheral blood of 12 healthy term 
newborns, 17 infants, 73 children, and 58 adults (19 adults for DDT). The regression lines are shown. (c) Scatterplot comparing MIF to DDT concentrations in paired 
measurements from all age groups. The regression line is shown. Data from (a) was obtained from Ref. (33).
Table 1 | Macrophage migration inhibitory factor (MiF) and d-dopachrome tautomerase (DDT) plasma concentrations in different age groups.
N MiF (ng/ml) DDT (ng/ml)
Median [interquartile range (iQr)] Mean (sD) Median (iQr) Mean (sD)
Fetusesa 15 48.9c (33.2–65.0) 51.9 (23.6) 29.6 (18.9–45.6) 31.5 (14.5)
Term newborns (day 0)b 60 82.6c (66.1–115.4) 91.9 (51.2) 52.0c (43.9–72.4) 61.1 (27.1)
Term newborns (day 4) 12 109.5c (76.5–159.5) 114.1 (43.1) 121.6c,d (74.1–137.3) 107.8 (36.0)
Infants (1–12 months) 17 7.4 (6.6–10.8) 8.5 (3.2) 14.6 (11.2–19.6) 15.0 (4.7)
Children (1–16 years) 73 5.2 (3.4–7.7) 6.3 (3.7) 12.5 (9.1–16.3) 13.3 (5.1)
Adults (>16 years) 58e 5.7 (4.0–8.3) 7.1 (4.5) 16.8 (14.1–25.4) 18.3 (7.6)
aMedian gestational age: 27 weeks (IQR: 25–29).
bBlood was collected from the umbilical vein.
cP < 0.05 versus infants, children, and adults.
dP < 0.05 versus fetuses, infants, children, and adults.
eDDT levels were measured in 19 adults.
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concentrations in UV were not influenced by gender, mode of 
delivery, maternal group B streptococcal status, intrapartum 
antibiotic prophylaxis, UA and UV pH, and Apgar scores at 1, 5, 
and 10 min.
associations between MiF and  
DDT levels and blood cells
To evaluate whether MIF and DDT levels are associated with 
specific cell types, we performed a complete blood count in UV 
blood of 25 healthy term newborns. UV MIF levels were not 
influenced by total leukocyte count, lymphocytes, monocytes, 
granulocytes, platelets, erythrocytes, hemoglobin, and hemato-
crit. UV DDT levels negatively correlated with monocyte levels 
(R = −0.46, P =  0.02), but no correlation was observed with 
other cell types. Next, we investigated whether leukocyte subsets 
isolated from newborns and adults release different amounts of 
MIF. After 24 h of culture, neutrophils, monocytes, and T cells 
from adults released higher amounts of MIF compared to new-
born cells (Figure 4). However, no difference in MIF secretion 
between adult and newborn neutrophils, monocytes, B cells, and 
T cells was observed at 48 h. Therefore, the large interindividual 
variations in MIF and DDT observed at birth are not associated 
with differences in the main demographic and clinical charac-
teristics or with the predominance of specific blood cell subtype. 
Moreover, newborn leukocyte subsets do not release higher levels 
of MIF in vitro compared to adult leukocyte subsets.
FigUre 2 | comparison of umbilical artery (Ua) to umbilical vein (UV) 
macrophage migration inhibitory factor (MiF) and d-dopachrome 
tautomerase (DDT) plasma concentrations. Scatterplot comparing MIF 
(a) and DDT (b) plasma concentrations in UA and UV in 86 (a) and 88 (b) 
paired measurements from preterm and term newborns. The regression lines 
are shown.
Table 2 | clinical characteristics of the newborns included in measurements of macrophage migration inhibitory factor and d-dopachrome 
tautomerase concentrations in umbilical cord blood.
Preterm newborns (n = 34) Term newborns (n = 60)
Maternal group B streptococcal status, n (%)
Positive 3 (9) 6 (10)
Negative 25 (74) 39 (65)
Unknown 6 (18) 15 (25)
Intrapartum antibiotic prophylaxis, n (%) 7 (21) 6 (10)
Antenatal steroids, n (%) 31 (91) 3 (5)
Mode of delivery, n (%)
Vaginal 6 (18) 30 (50)
Emergency cesarean section 16 (47) 3 (5)
Elective cesarean section 12 (35) 27 (45)
Male gender, n (%) 22 (65) 26 (43)
Median gestational age at birth, weeks [interquartile range (IQR)] 34 (32–36) 39 (39–40)
Median birthweight, g (IQR) 1,960 (1,665–2,295) 3,440 (3,280–3,670)
Median umbilical artery pH (IQR) 7.30 (7.26–7.33) 7.27 (7.21–7.30)
Median umbilical vein pH (IQR) 7.35 (7.31–7.37) 7.33 (7.29–7.37)
Median 1 min Apgar score (IQR) 9 (7–9) 9 (9–9)
Median 5 min Apgar score (IQR) 9 (8–9) 10 (9–10)
Median 10 min Apgar score (IQR) 10 (9–10) 10 (10–10)
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associations between MiF and DDT 
levels, VegF, and cytokines
Macrophage migration inhibitory factor and DDT are induced 
during hypoxia and inflammation (35, 45). We tested whether 
MIF and DDT levels correlate with VEGF, an angiogenic protein 
upregulated by hypoxia-inducible factor (HIF)-1α under hypoxic 
conditions, and inflammatory cytokines during development. 
Circulating levels of VEGF were higher in fetuses (median 
1,423  pg/ml, IQR 1,065–4,102) and in preterm newborns at 
birth (1,551  pg/ml, 1,064–2,441) compared to infants (676  pg/
ml, 527–810), children (485 pg/ml, 360–639), and adults (486 pg/
ml, 420–665) (P < 0.05). In term newborns, VEGF levels were 
higher at birth (1,090 pg/ml, 825–1,918) and on postnatal day 4 
(1,476 pg/ml, 1,161–2,512) compared to children (P = 0.05 and 
P < 0.05 versus VEGF levels at birth and on postnatal day 4) and 
adults (P = 0.06 and P < 0.05 versus VEGF levels at birth and on 
postnatal day 4). Overall, VEGF strongly correlated with MIF and 
DDT (R = 0.70, P < 0.0001 for MIF and R = 0.65, P < 0.0001 for 
DDT; Figure 5). Median concentrations of IL-1β, IL-6, and TNF 
were below the limit of quantification in all age groups confirm-
ing that, contrary to MIF and DDT, circulating levels of classical 
inflammatory cytokines are very low in the absence of infectious 
or inflammatory disease. Median levels of the IL-8 were 3.9 pg/
ml (1.1–15.5) in fetuses and 6.1 pg/ml (1.1–49.2) in the UV of 
preterm newborns but were below the detection limit in term 
newborns, infants, children, and adults.
MiF and DDT levels in Peripheral  
blood of Very Preterm infants
Preterm newborns are at risk of developing severe complica-
tions such as BPD and LOS. Association between MIF and DDT 
expression levels and outcome of preterm birth was explored by 
measuring MIF and DDT concentrations in the plasma of 50 very 
preterm infants (gestational age 26–31 weeks) on postnatal day 
6, prior to the development of BPD and LOS. Clinical charac-
teristics of the patients are presented in Table 4. Among the 50 
patients, 25 (50%) developed BPD and/or LOS, with 21 (42%) 
developing BPD, and 14 (28%) developing LOS. One patient died 
at 14 days of age, following LOS. MIF and DDT concentrations 
(median, IQR) were lower in infants who developed BPD and/or 
LOS than in those who did not develop these complications (MIF: 
45.9  ng/ml, 29.8–78.2 versus 75.7  ng/ml, 52.1–89.6, P =  0.04; 
DDT: 96.8  ng/ml, 56.7–146.2 versus 162.1  ng/ml, 113.6–223.6, 
P  =  0.004; Figures  6A,B). Exploratory multivariate analyses 
adjusted for birthweight confirmed that lower concentrations 
of MIF and DDT were associated with an increased risk of the 
composite outcome of BPD and/or LOS in this cohort (P = 0.054 
and P = 0.017, respectively).
Levels of VEGF, IL-1β, IL-6, IL-8, and TNF were measured 
in the 50 very preterm newborns and were compared to MIF 
and DDT levels. VEGF concentrations were 2,582 pg/ml (826–
5,293) and did not correlate with MIF or DDT concentrations 
(R =  0.21, P =  0.14 for MIF and R =  0.25, P =  0.1 for DDT). 
Median concentrations of IL-1β, IL-6, and TNF were below the 
limit of quantification. IL-8 concentrations were 42.6  pg/ml 
FigUre 5 | comparison of macrophage migration inhibitory factor 
(MiF) and d-dopachrome tautomerase (DDT) to vascular endothelial 
growth factor (VegF) plasma concentrations. Scatterplot comparing MIF 
(a) and DDT (b) to VEGF plasma concentrations in paired measurements 
from 14 fetuses, 14 preterm and 18 term newborns (umbilical vein), and from 
peripheral blood of 11 term newborns (on postnatal day 4), 17 infants, 14 
children, and 15 adults. The regression lines are shown.
FigUre 4 | Macrophage migration inhibitory factor (MiF) secretion by 
newborn and adult leukocyte subsets. Neutrophils, monocytes, B cells, 
and T cells from healthy term newborns (white bars) and adult volunteers 
(black bars) were cultured in RPMI medium supplemented with 10% FCS. 
MIF levels were measured by enzyme-linked immunosorbent assay in 
supernatant collected at 24 and 48 h. Data represent means ± SEM of five to 
nine independent experiments performed in triplicates (*P < 0.05).
Table 3 | MiF and DDT plasma concentrations in the UV and Ua of preterm and term newborns.
MiF (ng/ml) DDT (ng/ml)
N Median (iQr) Mean (sD) N Median (iQr) Mean (sD)
Preterm newborns, UV 29 58.3 (45.6–84.9) 72.0 (40.4) 30 58.7 (44.3–88.6) 76.2 (49.2)
Preterm newborns, UA 31 61.7 (51.8–95.1) 72.8 (32.5) 32 55.6 (39.7–74.9) 65.0 (37.6)
Term newborns, UV 60 82.6 (66.1–115.4) 91.9 (51.2) 60 52.0 (43.9–72.4) 61.1 (27.1)
Term newborns, UA 59 66.9 (53.0–95.7) 80.7 (44.8) 60 58.9 (41.5–71.8) 60.1 (27.0)
UV, umbilical vein; UA, umbilical artery; IQR, interquartile range; MIF, macrophage migration inhibitory factor; DDT, D-dopachrome tautomerase.
FigUre 3 | Umbilical cord blood concentrations of macrophage 
migration inhibitory factor (MiF) and d-dopachrome tautomerase 
(DDT) in preterm and term newborns. Scatterplot showing MIF (a,b) and 
DDT (c,D) concentrations in the umbilical vein versus gestational age and 
birthweight of 30 preterm and 60 term newborns. The regression lines are 
shown.
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(19.8–89.8) and correlated with MIF and DDT concentrations 
(R = 0.52, P = 0.0003 for MIF and R = 0.42, P = 0.004 for DDT; 
Figures 7A,B).
DiscUssiOn
This is the first study investigating MIF and DDT plasma levels 
in a large cohort of individuals ranging from fetuses to adults. 
Both mediators circulate at baseline in healthy subjects, with a 
strong correlation between MIF and DDT plasma concentrations 
and striking age-dependent fluctuations. Highest concentrations 
of >100  ng/ml were measured on postnatal day 4, a situation 
unique for cytokines that usually do not reach such levels except 
in extreme pathological situations. MIF and DDT levels dropped 
7- to 20-fold to reach adult levels during the first months of life.
Plasma levels of MIF and DDT were high in fetuses and 
increased further at birth, suggesting that both the fetal 
environment and the adaptive changes occurring during 
delivery could contribute to MIF and DDT circulating pools in 
newborns. Whether MIF and DDT mostly originate from the 
fetus or the placenta remains an open question given that their 
concentrations in the blood flowing in the UA and UV were com-
parable. The fetal environment is characterized by low oxygen 
tension and high concentrations of steroid hormones such as 
estradiol and progesterone that could both stimulate MIF and 
DDT production by the placenta and the fetus. Indeed, MIF and 
DDT are hypoxia-inducible genes (45, 46). VEGF promotes fetal 
vascular and pulmonary development and is tightly regulated by 
HIF activity (47). VEGF levels were higher in fetuses and new-
borns, compared to children and adults, and strongly correlated 
with MIF and DDT levels. This is in line with previous studies 
showing that MIF induces secretion of VEGF in several cancer 
FigUre 7 | comparison of macrophage migration inhibitory factor 
(MiF) and d-dopachrome tautomerase (DDT) to il-8 plasma 
concentrations in very preterm newborns. Scatterplot comparing MIF (a) 
and DDT (b) to IL-8 plasma concentrations in paired measurements from 50 
very preterm newborns. The regression lines are shown.
FigUre 6 | Macrophage migration inhibitory factor (MiF) and 
d-dopachrome tautomerase (DDT) plasma concentrations in 
peripheral blood of very preterm newborns. MIF (a) and DDT (b) plasma 
concentrations were measured on postnatal day 6 in 25 very preterm 
newborns who subsequently developed bronchopulmonary dysplasia and/or 
late-onset sepsis and in 25 preterm newborns who did not develop these 
complications. The median and interquartile range are shown.
Table 4 | clinical characteristics of 50 preterm newborns included in measurements of macrophage migration inhibitory factor and d-dopachrome 
tautomerase concentrations in peripheral blood on postnatal day 6.
Preterm newborns without 
bronchopulmonary dysplasia (bPD) 
and/or late-onset sepsis (n = 25)
Preterm newborns with bPD and/or 
late-onset sepsis (n = 25)
P value
Antenatal steroids, n (%) 24 (96) 22 (88) 0.61
Prelabor rupture of membranes, n (%) 7 (28) 7 (28) 1.00
Preclampsia, n (%) 6 (24) 2 (8) 0.29
Histological chorioamnionitis, n (%) 12 (48) 10 (40) 0.77
Vaginal delivery, n (%) 3 (12) 3 (12) 1.00
Male gender, n (%) 11 (44) 12 (48) 1.00
Median gestational age at birth, weeks [interquartile range (IQR)] 31 (30–31) 27 (26–27) <0.0001
Median birthweight, g (IQR) 1,510 (1,270–1,755) 870 (795–1,065) <0.0001
Median umbilical artery pH (IQR) 7.35 (7.32–7.37) 7.34 (7.30–7.40) 0.99
Median 5 min Apgar score (IQR) 7 (6–9) 5 (3–7) 0.004
Median 10 min Apgar score (IQR) 8 (8–9) 7 (6–8) 0.13
Mechanical ventilation, n (%) 6 (24) 20 (80) 0.001
BPDa, n (%) 0 21 (84) <0.0001
Medically treated patent ductus arteriosus, n (%) 6 (24) 18 (72) 0.002
Surgically treated patent ductus arteriosus, n (%) 0 8 (32) 0.008
Blood culture proven early-onset sepsis, n (%) 0 1 (4) 1.00
Blood culture proven late-onset sepsis, n (%) 0 14 (56) 0.0001
Necrotizing enterocolitisb, n (%) 0 2 (8) 0.50
Retinopathy of prematurity, n (%) 0 6 (24) 0.03
Intraventricular hemorrhage, n (%) 1 (4) 12 (48) 0.06
Periventricular leukomalacia, n (%) 0 3 (12) NA
Death, n (%) 0 1 (4) NA
aDefined as requirement for supplemental oxygen for more than 28 days.
bBell stage ≥2.
NA, not applicable.
7
Roger et al. MIF and DDT Throughout Life
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 26
cell lines (48–50) and that MIF-deficient mice express reduced 
levels of VEGF in the lungs (27). Elevated MIF concentrations at 
birth were not associated with a predominance of specific leuko-
cyte subsets or an increased capacity of newborn leukocytes to 
secrete MIF in vitro. However, steroids produced by the placenta 
and the fetal adrenal gland can stimulate MIF secretion by new-
born monocytes (33). Moreover, circulating leukocyte counts are 
at least twofold higher at birth than in adults (51). Therefore, a 
combination of high circulating levels of steroid hormones acting 
on a high number of leukocytes and a relatively low oxygen ten-
sion in utero could contribute to the strikingly elevated levels of 
MIF and DDT observed at birth.
The immune system is shaped by particular constrains during 
the fetal and neonatal periods, as illustrated by age-dependent 
variations in blood concentrations of pro-inflammatory and 
anti-inflammatory mediators (52). We did not detect measurable 
levels of IL-1β, IL-6, IL-8, and TNF in healthy term newborns, 
suggesting that elevated MIF and DDT levels at birth do not reflect 
systemic inflammation. In contrast, estradiol, progesterone, 
adenosine, and prostaglandins circulate at high concentrations 
perinatally (42, 53–55) and provide a skewed anti-inflammatory 
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milieu that preserves gestation and contributes to maintain 
tolerance to postnatal microbial colonization. Yet, this comes at 
the expense of weakening the ability to mount efficient immune 
responses against pathogens during the neonatal period (52, 56). 
Indeed, newborns are particularly susceptible to development 
of severe bacterial infections (57, 58). We have recently shown 
that MIF sustains microbial product-induced cell activation 
and cytokine production and counterregulates adenosine and 
prostaglandin E2-mediated immune suppression in newborn 
monocytes (33). Therefore, high levels of MIF, and possibly DDT, 
may be part of a counterregulatory mechanism to balance innate 
immune responses perinatally.
Macrophage migration inhibitory factor promotes lung 
development and protects preterm mice from neonatal respira-
tory distress syndrome and hyperoxia-induced lung injury (27, 
59). We report lower expression of MIF and DDT on postnatal 
day 6 in the circulation of very preterm newborns who subse-
quently developed BPD and/or LOS, two major complications of 
preterm birth. This is in line with the observation that MIF levels 
in tracheal aspirates obtained within the first 2 days of life are 
reduced in preterm infants who develop BPD (27, 30). Studies 
on the role of DDT have been limited to adults in humans and 
animals so far (34–36, 45, 60–62), and we do not known to which 
extend DDT impacts, like MIF, on lung development and innate 
immune responses in early life. Interestingly, IL-8 was detected in 
fetuses and preterm newborns, but not in term infants, children, 
and adults. In very preterm newborns, IL-8 levels measured on 
postnatal day 6 correlated with MIF and DDT. The frequency of 
circulating IL-8 producing CD4 T cells that can activate protec-
tive immune responses is fivefold higher in neonates than in 
adults (63). While MIF can stimulate IL-8 production by a variety 
of cell types including T cells (49, 50, 64), it remains to be deter-
mined whether MIF is implicated in T cell function in newborns. 
Overall, our results support a role for MIF in host defenses during 
the neonatal period.
Interindividual variations of circulating MIF levels have been 
analyzed in the context of MIF polymorphisms in patients with 
inflammatory, autoimmune, and infectious diseases (14, 15). Yet, 
no polymorphisms of the DDT gene have been reported. While 
carriage of high expression MIF alleles was generally associated 
with more severe complications and poor outcome, it has also been 
associated with survival in patients with community-acquired 
pneumonia (17, 65, 66). Our findings of higher MIF levels in 
infants who did not develop BPD or LOS are consistent with a 
previous study showing an association between carriage of a high 
expression MIF allele and a lower incidence of BPD in preterm 
newborns (30). We did not determine the MIF genotype of the 
very preterm newborns because genetic material was unavailable 
and because such a study would be strongly underpowered con-
sidering MIF allele frequencies and patient number (14, 16, 17). 
A nationwide pediatric sepsis cohort study has been launched 
in Switzerland and will address the relationship between MIF 
and DDT gene polymorphisms and expression levels and clinical 
outcome (58, 67).
The strengths of this study include its large size and the fact 
that it represents the first evaluation of MIF and DDT concen-
trations throughout life. Few studies, and none in the pediatric 
population, have investigated DDT plasma concentrations and 
have compared MIF to DDT levels (35–37). This study has several 
limitations. For ethical reasons, it was not possible to obtain 
sequential blood samples over a prolonged period in newborns, 
infants, and children. To establish age-specific reference values, 
we pooled samples from several cohorts covering a wide age 
range. Fetal samples were obtained prior to therapeutic abortions 
for a range of congenital malformations or chromosomal abnor-
malities, minimizing the possible impact of a specific condition 
on MIF and DDT levels (38). Samples were obtained in infants 
and children undergoing general anesthesia for elective surgery. 
As blood collection occurred upon induction of anesthesia, it is 
unlikely that physiological changes due to surgery could have 
altered MIF and DDT levels.
In conclusion, circulating concentrations of MIF and DDT 
are tightly correlated and change significantly with age, with the 
highest levels in newborns and the lowest levels in adults. The 
present study provides age-specific plasma concentrations of MIF 
and DDT in healthy individuals, which may serve to establish 
cutoff values in future studies. Moreover, our observations open 
the venue for future studies investigating whether MIF and DDT 
levels during the first week of life could be used as biomarkers to 
help predicting the occurrence of later complications in preterm 
newborns. Future studies should also examine associations 
between functional MIF polymorphisms and susceptibility to 
neonatal and pediatric sepsis and BPD, and severity of these 
diseases.
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